Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AbbVie and Pfizer lead rheumatoid arthritis digital marketing space in Australia amid biosimilars competition, says GlobalData

The rheumatoid arthritis (RA) treatment landscape in Australia is well established with several novel disease-modifying anti-rheumatic drugs (DMARDs). However, stiff biosimilars competition is expected to impact the leading drugs — AbbVie’s Humira and Pfizer’s Enbrel. Against this backdrop, the pharma giants are offering maximum support to RA patients through digital channels, says GlobalData, a leading […]
Read more

Positive long-term data from Roche’s Evrysdi will consolidate its strong position in SMA market, says GlobalData

Following Roche’s announcement of new 2-year data from Part 2 of FIREFISH, a Phase II/III global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA); Alessio Brunello, Managing Analyst at GlobalData, a leading data and analytics company, offers his view: “Roche’s Evrysdi continues to improve […]
Read more

University Technology Licensing Program will boost novel drug development, says GlobalData

The University Technology Licensing Program (UTLP) was created to improve innovation in multiple sectors and facilitate more efficient licensing between commercial companies and the 15 universities in the program. The UTLP participating universities have a sizeable pipeline of over 240 early-stage drugs that could be out-licensed, say GlobalData, a leading data and analytics company. The […]
Read more

Singapore leads medical tourism within APAC with Novartis’ Kymriah approval, says GlobalData

The inherent heterogeneity of diseases such as cancer is driving the field of personalized (precision) therapies. Within personalized therapies, chimeric antigen receptor (CAR-T) therapies are gaining traction. With the approval of Novartis’ Kymriah, Singapore is now all set to deliver the transformative treatment for cancers and takes the lead in medical tourism within Asia-Pacific (APAC), […]
Read more

COVID-19 survivors may face long-term complications, says GlobalData

Given recent findings that nearly one-third of previously hospitalized COVID-19 patients in the UK are readmitted for further treatment within five months after infection, and one in eight COVID-19 patients died in that same timeframe, further follow-up on the long-term effects of the disease needs to be conducted, along with treatments to prevent these outcomes, […]
Read more

Asthma low patient adherence shows need for personalized and convenient medications, says GlobalData

Primary research by data and analytics company GlobalData has revealed that 80% of asthma patients do not take their medication effectively. The reasons for this poor patient adherence are numerous and can include poor inhaler technique, poor perception, complex regimens and the cost of medication. Tiffany Chan, Immunology Analyst at GlobalData, discusses what medicines are […]
Read more

World Parkinson’s Day 2021: Urgent need for disease-modifying drugs to halt disease progression, says GlobalData

There are diverse development strategies and trends in the Parkinson’s disease (PD) treatment at present, however only a few of them address the pressing need for a disease-modifying therapy (DMT). This reflects the various complexities in the process of understanding the exact pathophysiology of the disease through bringing new therapies into this market. Therefore, if […]
Read more

AstraZeneca needs to regain public trust by showing benefits of COVID-19 vaccine far outweigh risks, says GlobalData

Following the news that the European Medicines Agency (EMA) has confirmed a possible link between very rare cases of unusual blood clots after vaccination with AstraZeneca’s COVID-19 vaccine Vaxzevria; Philipp Rosenbaum, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “AstraZeneca has had its fair share of bad luck […]
Read more

Immuno-Oncology the most transformative treatment since chemotherapy is set to benefit more patients

Immuno-oncology (IO) agents, particularly immune checkpoint inhibitors (ICIs) and CAR-T cell therapies, have extended the survival of patients in many cancer types and current investigational approaches in the industry and academia will lead to even further clinical improvement, says GlobalData, a leading data and analytics company. The company’s latest report, ‘Immuno-Oncology – Market Analysis, Trends, […]
Read more

Newron’s Xadago set to reach $246m by 2029 with new label extension potential in PD-LID, says GlobalData

Newron Pharmaceuticals and Zambon’s planned pivotal trial to evaluate a label extension for Xadago (safinamide) in patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID) is a strategic approach to boost Xadago’s peak sales and strengthen its competitive advantage in the PD space. This strategy usually helps companies to expand their existing patient pool and capitalize on […]
Read more
1 … 65 66 67 68 69 … 108